Use of lipid nanocarriers to improve oral delivery of vitamins

Nutrients

Volumn 11, Issue 1, 2019, Pages

  Hsu, Ching Yun ^a   Wang, Pei Wen ^b   Alalaiwe, Ahmed ^c   Lin, Zih Chan ^d   Fang, Jia You ^a,d,e  

^a CHANG GUNG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Taiwan)

^b CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c PRINCE SATTAM BIN ABDULAZIZ UNIVERSITY   (Saudi Arabia)

^d CHANG GUNG UNIVERSITY   (Taiwan)

^e CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

Bioavailability; Lipid nanocarrier; Nutrient; Oral absorption; Vitamin

Indexed keywords

ALPHA TOCOPHEROL; ALPHA TOCOTRIENOL; ASCORBIC ACID; CYANOCOBALAMIN; DRUG CARRIER; EMULSIFYING AGENT; NANOCARRIER; RETINOL; SEOCALCITOL; SOLID LIPID NANOPARTICLE; THIAMINE; TOCOFERSOLAN; VITAMIN; VITAMIN B GROUP; VITAMIN D; VITAMIN K GROUP; XANTHOPHYLL; LIPID; NANOPARTICLE;

ALZHEIMER DISEASE; BIOTRANSFORMATION; BLEEDING; BLOOD CLOTTING; BONE METABOLISM; CARDIOVASCULAR DISEASE; COLON CANCER; DNA SYNTHESIS; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG HALF LIFE; DRUG RELEASE; DRUG SOLUBILITY; DRUG STABILITY; HUMAN; IMMUNE STATUS; INOTROPISM; LIPOLYSIS; LIPOPHILICITY; MEMBRANE PERMEABILITY; MEMBRANE TRANSPORT; MICROEMULSION; NANOEMULSION; NANOENCAPSULATION; NANOMEDICINE; NEURITIS; NONHUMAN; ORAL ABSORPTION; PHARMACOKINETICS; REVIEW; VITAMIN DEFICIENCY; VITAMIN SUPPLEMENTATION; BIOAVAILABILITY; CHEMISTRY; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; BIOLOGICAL AVAILABILITY; DRUG CARRIERS; HUMANS; LIPIDS; NANOPARTICLES; VITAMINS;

EID: 85059497244     PISSN: None     EISSN: 20726643     Source Type: Journal    
DOI: 10.3390/nu11010068     Document Type: Review

References (142)

1. Choonara, B.F.; Choonara, Y.E.; Kumar, P.; Bijukumar, D.; du Toit, L.C.; Pillay, V. A review of advanced oral drug delivery technologies facilitating the protection and absorption of protein and peptide molecules. Biotechnol. Adv. 2014, 32, 1269–1282. [CrossRef] [PubMed]
2. Tyagi, P.; Pechenov, S.; Anand Subramony, J. Oral peptide delivery: Translational challenges due to physiological effects. J. Control. Release 2018, 287, 167–176. [CrossRef] [PubMed]
3. Rein, M.J.; Renouf, M.; Cruz-Hernandez, C.; Actis-Goretta, L.; Thakkar, S.K.; da Silva Pinto, M. Bioavailability of bioactive food compounds: A challenging journey to bioefficacy. Br. J. Clin. Pharmacol. 2013, 75, 588–602. [CrossRef] [PubMed]
4. Rumondor, A.C.F.; Dhareshwar, S.S.; Kesisoglou, F. Amorphous solid dispersions or prodrugs: Complementary strategies to increase drug absorption. J. Pharm. Sci. 2016, 105, 2498–2508. [CrossRef] [PubMed]
5. Weiss, J.; Decker, E.A.; McClements, D.J.; Kristbergsson, K.; Helgason, T.; Awad, T. Solid lipid nanoparticles as delivery systems for bioactive food components. Food Biophys. 2008, 3, 146–154. [CrossRef]
6. Suchaoin, W.; Bernkop-Schnürch, A. Nanocarriers protecting toward an intestinal pre-uptake metabolism. Nanomedicine 2017, 12, 255–269. [CrossRef] [PubMed]
7. Tagami, T.; Ozeki, T. Recent trends in clinical trials related to carrier-based drugs. J. Pharm. Sci. 2017, 106, 2219–2226. [CrossRef]
8. Chakraborty, S.; Shukla, D.; Mishra, B.; Singh, S. Lipid-an emerging platform for oral delivery of drugs with poor bioavailability. Eur. J. Pharm. Biopharm. 2009, 73, 1–15. [CrossRef]
9. Dumont, C.; Bourgeois, S.; Fessi, H.; Jannin, V. Lipid-based nanosuspensions for oral delivery of peptides, a critical review. Int. J. Pharm. 2018, 541, 117–135. [CrossRef]
10. Joyce, P.; Whitby, C.P.; Prestidge, C.A. Nanostructuring biomaterials with specific Activities towards digestive enzymes for controlled gastrointestinal absorption of lipophilic bioactive molecules. Adv. Colloid Interface Sci. 2016, 237, 52–75. [CrossRef]
11. Akula, S.; Gurram, A.K.; Devireddy, S.R. Self-microemulsifying drug delivery systems: An attractive strategy for enhanced therapeutic profile. Int. Sch. Res. Notices 2014, 2014, 964051. [CrossRef] [PubMed]
12. Managuli, R.S.; Raut, S.Y.; Reddy, M.S.; Mutalik, S. Targeting the intestinal lymphatic system: A versatile path for enhanced oral bioavailability of drugs. Expert Opin. Drug Deliv. 2018, 15, 787–804. [CrossRef] [PubMed]
13. Negi, L.M.; Tariq, M.; Talegaonkar, S. Nano scale self-emulsifying oil based carrier system for improved oral bioavailability of camptothecin derivative by P-Glycoprotein modulation. Colloids Surf. B Biointerfaces 2013, 111, 346–353. [CrossRef] [PubMed]
14. Roger, E.; Lagarce, F.; Garcion, E.; Benoit, J.P. Lipid nanocarriers improve paclitaxel transport throughout human intestinal epithelial cells by using vesicle-mediated transcytosis. J. Control. Release 2009, 140, 174–181. [CrossRef] [PubMed]
15. Howe, S.E.; Lickteig, D.J.; Plunkett, K.N.; Ryerse, J.S.; Konjufca, V. The uptake of soluble and particulate antigens by epithelial cells in the mouse small intestine. PLoS ONE 2014, 9, e86656. [CrossRef] [PubMed]
16. Shi, L.L.; Xie, H.; Lu, J.; Cao, Y.; Liu, J.Y.; Zhang, X.X.; Zhang, H.; Cui, J.H.; Cao, Q.R. Positively charged surface-modified solid lipid nanoparticles promote the intestinal transport of docetaxel through multifunctional mechanisms in rats. Mol. Pharm. 2016, 13, 2667–2676. [CrossRef]
17. Xu, Y.; Zheng, Y.; Wu, L.; Zhu, X.; Zhang, Z.; Huang, Y. Novel solid lipid nanoparticle with endosomal escape function for oral delivery of insulin. ACS Appl. Mater. Interfaces 2018, 10, 9315–9324. [CrossRef]
18. Li, Q.; Xia, D.; Tao, J.; Shen, A.; He, Y.; Gan, Y.; Wang, C. Self-assembled core-shell-type lipid-polymer hybrid nanoparticles: Intracellular trafficking and relevance for oral absorption. J. Pharm. Sci. 2017, 106, 3120–3130. [CrossRef]
19. Pouton, C.W.; Porter, C.J. Formulation of lipid-based delivery systems for oral administration: Materials, methods and strategies. Adv. Drug Deliv. Rev. 2008, 60, 625–637. [CrossRef]
20. Kollipara, S.; Gandhi, R.K. Pharmacokinetic aspects and in vitro-in vivo correlation potential for lipid-based formulations. Acta Pharm. Sin. B 2014, 4, 333–349. [CrossRef]
21. Chatzidaki, M.D.; Mateos-Diaz, E.; Leal-Calderon, F.; Xenakis, A.; Carrière, F. Water-in-oil microemulsions versus emulsions as carriers of hydroxytyrosol: An in vitro gastrointestinal lipolysis study using the pHstat technique. Food Funct. 2016, 7, 2258–2269. [CrossRef] [PubMed]
22. Fonte, P.; Nogueira, T.; Gehm, C.; Ferreira, D.; Sarmento, B. Chitosan-coated solid lipid nanoparticles enhance the oral absorption of insulin. Drug Deliv. Transl. Res. 2011, 1, 299–308. [CrossRef] [PubMed]
23. Kumar, D.H.L.; Sarkar, P. Encapsulation of bioactive compounds using nanoemulsions. Environ. Chem. Lett. 2018, 16, 59–70. [CrossRef]
24. Lopes, C.M.; Martins-Lopes, P.; Souto, E.B. Nanoparticulate carriers (NPC) for oral pharmaceutics and nutraceutics. Pharmazie 2010, 65, 75–82. [PubMed]
25. Zhang, Y.; Zhou, W.E.; Yan, J.Q.; Liu, M.; Zhou, Y.; Shen, X.; Ma, Y.L.; Feng, X.S.; Yang, J.; Li, G.H. A review of the extraction and determination methods of thirteen essential vitamins to the human body: An update from 2010. Molecules 2018, 23, 1484. [CrossRef] [PubMed]
26. Eggersdorfer, M.; Laudert, D.; Létinois, U.; McClymont, T.; Medlock, J.; Netscher, T.; Bonrath, W. One hundred years of vitamins-a success story of the natural sciences. Angew Chem. Int. Ed. Engl. 2012, 51, 12960–12990. [CrossRef] [PubMed]
27. Karaźniewicz-Łada, M.; Główka, A. A review of chromatographic methods for the determination of water-and fat-soluble vitamins in biological fluids. J. Sep. Sci. 2016, 39, 132–148. [CrossRef] [PubMed]
28. Langi, P.; Kiokias, S.; Varzakas, T.; Proestos, C. Carotenoids: From plants to food and feed industries. Methods Mol. Biol. 2018, 1852, 57–71. [PubMed]
29. Weber, D.; Grune, T. The contribution of β-carotene to vitamin A supply of humans. Mol. Nutr. Food Res. 2012, 56, 251–258. [CrossRef]
30. Borel, P.; Desmarchelier, C. Genetic variations associated with vitamin A status and vitamin A bioavailability. Nutrients 2017, 9, 246. [CrossRef]
31. O’Byrne, S.M.; Blaner, W.S. Retinol and retinyl esters: Biochemistry and physiology. J. Lipid Res. 2013, 54, 1731–1743. [CrossRef] [PubMed]
32. Vrolijk, M.F.; Opperhuizen, A.; Jansen, E.H.J.M.; Hageman, G.J.; Bast, A.; Haenen, G.R.M.M. The vitamin B6 paradox: Supplementation with high concentrations of pyridoxine leads to decreased vitamin B6 function. Toxicol. Vitro 2017, 44, 206–212. [CrossRef] [PubMed]
33. 12 in cow’s milk. Br. J. Nutr. 2012, 107, 61–66. [CrossRef]
34. 12 from dairy products using a pig model. Nutrients 2018, 10, 1134. [CrossRef] [PubMed]
35. Jacob, R.A.; Sotoudeh, G. Vitamin C function and status in chronic disease. Nutr. Clin. Care 2002, 5, 66–74. [CrossRef] [PubMed]
36. Carr, A.C.; Maggini, S. Vitamin C and immune function. Nutrients 2017, 9, 1211. [CrossRef]
37. Davis, J.L.; Paris, H.L.; Beals, J.W.; Binns, S.E.; Giordano, G.R.; Scalzo, R.L.; Schweder, M.M.; Blair, E.; Bell, C. Liposomal-encapsulated ascorbic acid: Influence on vitamin C bioavailability and capacity to protect against ischemia-reperfusion injury. Nutr. Metab. Insights 2016, 9, 25–30. [CrossRef]
38. Muñoz-Montesino, C.; Roa, F.J.; Peña, E.; González, M.; Sotomayor, K.; Inostroza, E.; Muñoz, C.A.; González, I.; Maldonado, M.; Soliz, C.; et al. Mitochondrial ascorbic acid transport is mediated by a low-affinity form of the sodium-coupled ascorbic acid transporter-2. Free Radic. Biol. Med. 2014, 70, 241–254. [CrossRef]
39. Bouillon, R.; Suda, T. Vitamin D: Calcium and bone homeostasis during evolution. Bonekey Rep. 2014, 3, 480. [CrossRef]
40. Reboul, E.; Goncalves, A.; Comera, C.; Bott, R.; Nowicki, M.; Landrier, J.F.; Jourdheuil-Rahmani, D.; Dufour, C.; Collet, X.; Borel, P. Vitamin D intestinal absorption is not a simple passive diffusion: Evidences for involvement of cholesterol transporters. Mol. Nutr. Food Res. 2011, 55, 691–702. [CrossRef]
41. Hodgkinson, A.J.; Wallace, O.A.M.; Kruger, M.C.; Prosser, C.G. Effect of the dietary delivery matrix on vitamin D3 bioavailability and bone mineralisation in vitamin-D3-deficient growing male rats. Br. J. Nutr. 2018, 119, 143–152. [CrossRef] [PubMed]
42. Szymańska, R.; Nowicka, B.; Kruk, J. Vitamin E-occurrence, biosynthesis by plants and functions in human nutrition. Mini Rev. Med. Chem. 2017, 17, 1039–1052. [CrossRef] [PubMed]
43. Azzi, A. Many tocopherols, one vitamin E. Mol. Aspects Med. 2018, 61, 92–103. [CrossRef] [PubMed]
44. Reboul, E. Vitamin E bioavailability: Mechanisms of intestinal absorption in the spotlight. Antioxidants 2017, 6, 95. [CrossRef] [PubMed]
45. Zou, W.; Noh, S.K.; Owen, K.Q.; Koo, S.I. Dietary L-carnitine enhances the lymphatic absorption of fat and alpha-tocopherol in ovariectomized rats. J. Nutr. 2005, 135, 753–756. [CrossRef] [PubMed]
46. Traber, M.G. Vitamin E inadequacy in humans: Causes and consequences. Adv. Nutr. 2014, 5, 503–514. [CrossRef] [PubMed]
47. Gong, Y.; Wu, Y.; Zheng, C.; Fan, L.; Xiong, F.; Zhu, J. An excellent delivery system for improving the oral bioavailability of natural vitamin E in rats. AAPS PharmSciTech 2012, 13, 961–966. [CrossRef]
48. Bruno, R.S.; Leonard, S.W.; Park, S.I.; Zhao, Y.; Traber, M.G. Human vitamin E requirements assessed with the use of apples fortified with deuterium-labeled alpha-tocopheryl acetate. Am. J. Clin. Nutr. 2006, 83, 299–304. [CrossRef]
49. Goncalves, A.; Roi, S.; Nowicki, M.; Dhaussy, A.; Huertas, A.; Amiot, M.J.; Reboul, E. Fat-soluble vitamin intestinal absorption: Absorption sites in the intestine and interactions for absorption. Food Chem. 2015, 172, 155–160. [CrossRef]
50. Shearer, M.J.; Okano, T. Key pathways and regulators of vitamin K function and intermediary metabolism. Annu. Rev. Nutr. 2018, 38, 127–151. [CrossRef]
51. van Hasselt, P.M.; Janssens, G.E.; Slot, T.K.; van der Ham, M.; Minderhoud, T.C.; Talelli, M.; Akkermans, L.M.; Rijcken, C.J.; van Nostrum, C.F. The influence of bile acids on the oral bioavailability of vitamin K encapsulated in polymeric micelles. J. Control. Release 2009, 133, 161–168. [CrossRef] [PubMed]
52. 1 after intravenous and oral administration to subjects on phenprocoumon therapy. Int. J. Pharm. 1988, 48, 223–230. [CrossRef]
53. Weber, S.; Zimmer, A.; Pardeike, J. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) for pulmonary application: A review of the state of the art. Eur. J. Pharm. Biopharm. 2014, 86, 7–22. [CrossRef] [PubMed]
54. Pathak, K.; Raghuvanshi, S. Oral bioavailability: Issues and solutions via nanoformulations. Clin. Pharmacokinet. 2015, 54, 325–357. [CrossRef] [PubMed]
55. Dokania, S.; Joshi, A.K. Self-microemulsifying drug delivery system (SMEDDS)-challenges and road ahead. Drug Deliv. 2015, 22, 675–690. [CrossRef] [PubMed]
56. Date, A.A.; Desai, N.; Dixit, R.; Nagarsenker, M. Self-nanoemulsifying drug delivery systems: Formulation insights, applications and advances. Nanomedicine 2010, 5, 1595–1616. [CrossRef] [PubMed]
57. Chen, C.H.; Chen, C.J.; Elzoghby, A.O.; Yeh, T.S.; Fang, J.Y. Self-assembly and directed assembly of lipid nanocarriers for prevention of liver fibrosis in obese rats: A comparison with the therapy of bariatric surgery. Nanomedicine 2018, 13, 1551–1566. [CrossRef] [PubMed]
58. Khan, A.W.; Kotta, S.; Ansari, S.H.; Sharma, R.K.; Ali, J. Potentials and challenges in self-nanoemulsifying drug delivery systems. Expert Opin. Drug Deliv. 2012, 9, 1305–1317. [CrossRef] [PubMed]
59. Rehman, F.U.; Shah, K.U.; Shah, S.U.; Khan, I.U.; Khan, G.M.; Khan, A. From nanoemulsions to self-nanoemulsions, with recent advances in self-nanoemulsifying drug delivery systems (SNEDDS). Expert Opin. Drug Deliv. 2017, 14, 1325–1340. [CrossRef] [PubMed]
60. Cole, E.T.; Cadé, D.; Benameur, H. Challenges and opportunities in the encapsulation of liquid and semi-solid formulations into capsules for oral administration. Adv. Drug Deliv. Rev. 2008, 60, 747–756. [CrossRef] [PubMed]
61. Tsai, M.J.; Wu, P.C.; Huang, Y.B.; Chang, J.S.; Lin, C.L.; Tsai, Y.H.; Fang, J.Y. Baicalein loaded in tocol nanostructured lipid carriers (tocol NLCs) for enhanced stability and brain targeting. Int. J. Pharm. 2012, 423, 461–470. [CrossRef] [PubMed]
62. Guo, Y.; Luo, J.; Tan, S.; Otieno, B.O.; Zhang, Z. The applications of Vitamin E TPGS in drug delivery. Eur. J. Pharm. Sci. 2013, 49, 175–186. [CrossRef] [PubMed]
63. Gao, F.; Zhang, Z.; Bu, H.; Huang, Y.; Gao, Z.; Shen, J.; Zhao, C.; Li, Y. Nanoemulsion improves the oral absorption of candesartan cilexetil in rats: Performance and mechanism. J. Control. Release 2011, 149, 168–174. [CrossRef] [PubMed]
64. Salvia-Trujillo, L.; Martín-Belloso, O.; McClements, D.J. Excipient nanoemulsions for improving oral bioavailability of bioactives. Nanomaterials 2016, 6, 17. [CrossRef] [PubMed]
65. Wibowo, D.; Zhao, C.X.; Middelberg, A.P. Emulsion-templated silica nanocapsules formed using bio-inspired silicification. Chem. Commun. 2014, 50, 11325–11328. [CrossRef] [PubMed]
66. McClements, D.J. Edible nanoemulsions: Fabrication, properties, and functional performance. Soft Matter 2011, 7, 2297–2316. [CrossRef]
67. Salvia-Trujillo, L.; Soliva-Fortuny, R.; Rojas-Graü, M.A.; McClements, D.J.; Martín-Belloso, O. Edible nanoemulsions as carriers of active ingredients: A review. Annu. Rev. Food Sci. Technol. 2017, 8, 439–466. [CrossRef]
68. Callender, S.P.; Mathews, J.A.; Kobernyk, K.; Wettig, S.D. Microemulsion utility in pharmaceuticals: Implications for multi-drug delivery. Int. J. Pharm. 2017, 526, 425–442. [CrossRef]
69. Ezzati Nazhad Dolatabadi, J.; Valizadeh, H.; Hamishehkar, H. Solid lipid nanoparticles as efficient drug and gene delivery systems: Recent breakthroughs. Adv. Pharm. Bull. 2015, 5, 151–159. [CrossRef]
70. Garcês, A.; Amaral, M.H.; Sousa Lobo, J.M.; Silva, A.C. Formulations based on solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) for cutaneous use: A review. Eur. J. Pharm. Sci. 2018, 112, 159–167. [CrossRef]
71. Zhou, X.; Zhang, X.; Ye, Y.; Zhang, T.; Wang, H.; Ma, Z.; Wu, B. Nanostructured lipid carriers used for oral delivery of oridonin: An effect of ligand modification on absorption. Int. J. Pharm. 2015, 479, 391–398. [CrossRef] [PubMed]
72. Beloqui, A.; Solinís, M.Á.; Rodríguez-Gascón, A.; Almeida, A.J.; Préat, V. Nanostructured lipid carriers: Promising drug delivery systems for future clinics. Nanomed. Nanotechnol. Biol. Med. 2016, 12, 143–161. [CrossRef] [PubMed]
73. Shah, A.V.; Desai, H.H.; Thool, P.; Dalrymple, D.; Serajuddin, A.T.M. Development of self-microemulsifying drug delivery system for oral delivery of poorly water-soluble nutraceuticals. Drug Dev. Ind. Pharm. 2018, 44, 895–901. [CrossRef] [PubMed]
74. Taha, E.I.; Al-Suwayeh, S.A.; Anwer, M.K. Preparation, in vitro and in vivo evaluation of solid-state self-nanoemulsifying drug delivery system (SNEDDS) of vitamin A acetate. J. Drug Target. 2009, 17, 468–473. [CrossRef] [PubMed]
75. Shanmugam, S.; Baskaran, R.; Balakrishnan, P.; Thapa, P.; Yong, C.S.; Yoo, B.K. Solid self-nanoemulsifying drug delivery system (S-SNEDDS) containing phosphatidylcholine for enhanced bioavailability of highly lipophilic bioactive carotenoid lutein. Eur. J. Pharm. Biopharm. 2011, 79, 250–257. [CrossRef] [PubMed]
76. Shah, N.H.; Carvajal, M.T.; Patel, C.I.; Infeld, M.H.; Malick, A.W. Self-emulsifying drug delivery systems (SEDDS) with polyglycolyzed glycerides for improving in vitro dissolution and oral absorption of lipophilic drugs. Int. J. Pharm. 1994, 106, 15–23. [CrossRef]
77. Grove, M.; Müllertz, A.; Nielsen, J.L.; Pedersen, G.P. Bioavailability of seocalcitol II: Development and characterisation of self-microemulsifying drug delivery systems (SMEDDS) for oral administration containing medium and long chain triglycerides. Eur. J. Pharm. Sci. 2006, 28, 233–242. [CrossRef] [PubMed]
78. Julianto, T.; Yuen, K.H.; Noor, A.M. Improved bioavailability of vitamin E with a self emulsifying formulation. Int. J. Pharm. 2000, 200, 53–57. [CrossRef]
79. Yap, S.P.; Yuen, K.H.; Wong, J.W. Pharmacokinetics and bioavailability of α-, γ-, and δ-tocotrienols under different food status. J. Pharm. Pharmacol. 2001, 53, 1–5. [CrossRef]
80. Yap, S.P.; Yuen, K.H. Influence of lipolysis and droplet size on tocotrienol absorption from self-emulsifying formulations. Int. J. Pharm. 2004, 281, 67–78. [CrossRef]
81. Mukhija, K.; Singhal, K.; Angmo, S.; Yadav, K.; Yadav, H.; Sandhir, R.; Singhal, N.K. Potential of alginate encapsulated ferric saccharate microemulsions to ameliorate iron deficiency in mice. Biol. Trace Elem. Res. 2016, 172, 179–192. [CrossRef]
82. Gibaud, S.; Attivi, D. Microemulsions for oral administration and their therapeutic applications. Expert Opin. Drug Deliv. 2012, 9, 937–951. [CrossRef] [PubMed]
83. Bali, V.; Bhavna Ali, M.; Baboota, S.; Ali, J. Potential of microemulsions in drug delivery and therapeutics: A patent review. Recent Pat. Drug Deliv. Formul. 2008, 2, 136–144. [CrossRef] [PubMed]
84. Salminen, H.; Gömmel, C.; Leuenberger, B.H.; Weiss, J. Influence of encapsulated functional lipids on crystal structure and chemical stability in solid lipid nanoparticles: Towards bioactive-based design of delivery systems. Food Chem. 2016, 190, 928–937. [CrossRef] [PubMed]
85. Lin, Y.K.; Chou, W.L.; Wang, P.W.; Yang, S.C.; Fang, J.Y. The use of therapeutic nanoparticulate systems for treating atopic dermatitis. Curr. Nanosci. 2018, 14, 3–16. [CrossRef]
86. Das, S.; Chaudhury, A. Recent advances in lipid nanoparticle formulations with solid matrix for oral drug delivery. AAPS PharmSciTech 2011, 12, 62–76. [CrossRef] [PubMed]
87. Lin, C.H.; Chen, C.H.; Lin, Z.C.; Fang, J.Y. Recent advances in oral delivery of drugs and bioactive natural products using solid lipid nanoparticles as the carriers. J. Food Drug Anal. 2017, 25, 219–234. [CrossRef] [PubMed]
88. Khosa, A.; Reddi, S.; Saha, R.N. Nanostructured lipid carriers for site-specific drug delivery. Biomed. Pharmacother. 2018, 103, 598–613. [CrossRef]
89. Liu, G.Y.; Wang, J.M.; Xia, Q. Application of nanostructured lipid carrier in food for the improved bioavailability. Eur. Food Res. Technol. 2012, 234, 391–398. [CrossRef]
90. Sato, Y.; Kobayashi, M.; Itagaki, S.; Hirano, T.; Noda, T.; Mizuno, S.; Sugawara, M.; Iseki, K. Pharmacokinetic properties of lutein emulsion after oral administration to rats and effect of food intake on plasma concentration of lutein. Biopharm. Drug Dispos. 2011, 32, 151–158. [CrossRef]
91. Sato, Y.; Joumura, T.; Nashimoto, S.; Yokoyama, S.; Takekuma, Y.; Yoshida, H.; Sugawara, M. Enhancement of lymphatic transport of lutein by oral administration of a solid dispersion and a self-microemulsifying drug delivery system. Eur. J. Pharm. Biopharm. 2018, 127, 171–176. [CrossRef] [PubMed]
92. Sen, C.K.; Khanna, S.; Rink, C.; Roy, S. Tocotrienols: The emerging face of natural vitamin E. Vitam. Horm. 2007, 76, 203–261.
93. Rasool, A.H.; Rahman, A.R.; Yuen, K.H.; Wong, A.R. Arterial compliance and vitamin E blood levels with a self emulsifying preparation of tocotrienol rich vitamin E. Arch. Pharm. Res. 2008, 31, 1212–1217.
94. Alqahtani, S.; Alayoubi, A.; Nazzal, S.; Sylvester, P.W.; Kaddoumi, A. Nonlinear absorption kinetics of self-emulsifying drug delivery systems (SEDDS) containing tocotrienols as lipophilic molecules: In vivo and in vitro studies. AAPS J. 2013, 15, 684–695. [CrossRef] [PubMed]
95. Alqahtani, S.; Alayoubi, A.; Nazzal, S.; Sylvester, P.W.; Kaddoumi, A. Enhanced solubility and oral bioavailability of γ-tocotrienol using a self-emulsifying drug delivery system (SEDDS). Lipids 2014, 49, 819–829. [CrossRef] [PubMed]
96. Westergren, T.; Kalikstad, B. Dosage and formulation issues: Oral vitamin E therapy in children. Eur. J. Clin. Pharmacol. 2010, 66, 109–118. [CrossRef] [PubMed]
97. Abu-Fayyad, A.; Behery, F.; Sallam, A.A.; Alqahtani, S.; Ebrahim, H.; El Sayed, K.A.; Kaddoumi, A.; Sylvester, P.W.; Carroll, J.L.; Cardelli, J.A.; et al. PEGylated γ-tocotrienol isomer of vitamin E: Synthesis, characterization, in vitro cytotoxicity, and oral bioavailability. Eur. J. Pharm. Biopharm. 2015, 96, 185–195. [CrossRef]
98. El-Say, K.M.; Ahmed, T.A.; Ahmed, O.A.A.; Hosny, K.M.; Abd-Allah, F.I. Self-nanoemulsifying lyophilized tablets for flash oral transmucosal delivery of vitamin K: Development and clinical evaluation. J. Pharm. Sci. 2017, 106, 2447–2456. [CrossRef]
99. Wu, Q.; Uluata, S.; Cui, L.; Wang, C.; Li, D.; Mcclements, J.; Decker, E.A. Physical and oxidation stability of self-emulsifying krill oil-in-water emulsions. Food Funct. 2016, 7, 3590–3598. [CrossRef]
100. Mannina, P.; Segale, L.; Giovannelli, L.; Bonda, A.F.; Pattarino, F. Self-emulsifying excipient platform for improving technological properties of alginate-hydroxypropylcellulose pellets. Int. J. Pharm. 2016, 499, 74–80. [CrossRef]
101. Raut, S.; Karzuon, B.; Atef, E. Using in situ Raman spectroscopy to study the drug precipitation inhibition and supersaturation mechanism of Vitamin E TPGS from self-emulsifying drug delivery systems (SEDDS). J. Pharm. Biomed. Anal. 2015, 109, 121–127. [CrossRef] [PubMed]
102. Wempe, M.F.; Wright, C.; Little, J.L.; Lightner, J.W.; Large, S.E.; Caflisch, G.B.; Buchanan, C.M.; Rice, P.J.; Wacher, V.J.; Ruble, K.M.; et al. Inhibiting efflux with novel non-ionic surfactants: Rational design based on vitamin E TPGS. Int. J. Pharm. 2009, 370, 93–102. [CrossRef] [PubMed]
103. Yang, S.; Gursoy, R.N.; Lambert, G.; Benita, S. Enhanced oral absorption of paclitaxel in a novel self-microemulsifying drug delivery system with or without concomitant use of P-glycoprotein inhibitors. Pharm. Res. 2004, 21, 261–270. [CrossRef] [PubMed]
104. Hendrikx, J.J.; Lagas, J.S.; Rosing, H.; Schellens, J.H.; Beijnen, J.H.; Schinkel, A.H. P-glycoprotein and cytochrome P450 3A act together in restricting the oral bioavailability of paclitaxel. Int. J. Cancer. 2013, 132, 2439–2447. [CrossRef] [PubMed]
105. Veltkamp, S.A.; Thijssen, B.; Garrigue, J.S.; Lambert, G.; Lallemand, F.; Binlich, F.; Huitema, A.D.; Nuijen, B.; Nol, A.; Beijnen, J.H.; et al. A novel self-microemulsifying formulation of paclitaxel for oral administration to patients with advanced cancer. Br. J. Cancer 2006, 95, 729–734. [CrossRef] [PubMed]
106. Valicherla, G.R.; Dave, K.M.; Syed, A.A.; Riyazuddin, M.; Gupta, A.P.; Singh, A.; Wahajuddin; Mitra, K.; Datta, D.; Gayen, J.R. Formulation optimization of docetaxel loaded self-emulsifying drug delivery system to enhance bioavailability and anti-tumor activity. Sci. Rep. 2016, 6, 26895. [CrossRef] [PubMed]
107. Ansermot, N.; Rebsamen, M.; Chabert, J.; Fathi, M.; Gex-Fabry, M.; Daali, Y.; Besson, M.; Rossier, M.; Rudaz, S.; Hochstrasser, D.; et al. Influence of ABCB1 gene polymorphisms and P-glycoprotein activity on cyclosporine pharmacokinetics in peripheral blood mononuclear cells in healthy volunteers. Drug Metab. Lett. 2008, 2, 76–82. [CrossRef]
108. Jain, S.; Kambam, S.; Thanki, K.; Jain, A.K. Cyclosporine A loaded self-nanoemulsifying drug delivery system (SNEDDS): Implication of a functional excipient based co-encapsulation strategy on oral bioavailability and nephrotoxicity. RSC Adv. 2015, 5, 49633–49642. [CrossRef]
109. Cho, W.; Kim, M.S.; Kim, J.S.; Park, J.; Park, H.J.; Cha, K.H.; Park, J.S.; Hwang, S.J. Optimized formulation of solid self-microemulsifying sirolimus delivery systems. Int. J. Nanomed. 2013, 8, 1673–1682.
110. Bajaj, A.; Rao, M.R.; Khole, I.; Munjapara, G. Self-nanoemulsifying drug delivery system of cefpodoxime proxetil containing tocopherol polyethylene glycol succinate. Drug Dev. Ind. Pharm. 2013, 39, 635–645. [CrossRef]
111. Miller, D.B.; Spence, J.D. Clinical pharmacokinetics of fibric acid derivatives (fibrates). Clin. Pharmacokinet. 1998, 34, 155–162. [CrossRef] [PubMed]
112. Wei, J.D.; Ho, H.O.; Chen, C.H.; Ke, W.T.; Chen, E.T.; Sheu, M.T. Characterisation of fenofibrate dissolution delivered by a self-microemulsifying drug-delivery system. J. Pharm. Pharmacol. 2010, 62, 1685–1696. [CrossRef] [PubMed]
113. Lin, Y.M.; Wu, J.Y.; Chen, Y.C.; Su, Y.D.; Ke, W.T.; Ho, H.O.; Sheu, M.T. In situ formation of nanocrystals from a self-microemulsifying drug delivery system to enhance oral bioavailability of fenofibrate. Int. J. Nanomed. 2011, 6, 2445–2457.
114. Goh, P.S.; Ng, M.H.; Choo, Y.M.; Amru, N.B.; Chuah, C.H. Production of nanoemulsions from palm-based tocotrienol rich fraction by microfluidization. Molecules 2015, 20, 19936–19946. [CrossRef] [PubMed]
115. Alayoubi, A.; Ayoub, N.M.; Malaviya, A.; Sylvester, P.W.; Nazzal, S. Entrapment into nanoemulsions potentiates the anticancer activity of tocotrienols against the highly malignant (+SA) mouse mammary epithelial cells. J. Nanosci. Nanotechnol. 2014, 14, 4002–4005. [CrossRef]
116. Qian, C.; Decker, E.A.; Xiao, H.; McClements, D.J. Nanoemulsion delivery systems: Influence of carrier oil on β-carotene bioaccessibility. Food Chem. 2012, 135, 1440–1447. [CrossRef] [PubMed]
117. Xia, Z.; McClements, D.J.; Xiao, H. Influence of physical state of β-carotene (crystallized versus solubilized) on bioaccessibility. J. Agric. Food Chem. 2015, 63, 990–997. [CrossRef]
118. Evans, M.; Ratcliffe, I.; Williams, P.A. Emulsion stabilisation using polysaccharide-protein complexes. Curr. Opin. Colloid Interf. Sci. 2013, 18, 272–282. [CrossRef]
119. Liu, F.; Ma, C.; Zhang, R.; Gao, Y.; McClements, D.J. Controlling the potential gastrointestinal fate of β-carotene emulsions using interfacial engineering: Impact of coating lipid droplets with polyphenol-protein-carbohydrate conjugate. Food Chem. 2017, 221, 395–403. [CrossRef]
120. Mun, S.; Kim, Y.R.; McClements, D.J. Control of β-carotene bioaccessibility using starch-based filled hydrogels. Food Chem. 2015, 173, 454–461. [CrossRef]
121. Huang, R.T.; Lu, J.F.; Inbaraj, B.S.; Chen, B.H. Determination of phenolic acids and flavonoids in Rhinacanthus nasutus (L.) kurz by high-performance-liquid-chromatography with photodiode-array detection and tandem mass spectrometry. J. Funct. Foods 2015, 12, 498–508. [CrossRef]
122. Ho, N.H.; Inbaraj, B.S.; Chen, B.H. Utilization of microemulsions from Rhinacanthus nasutus (L.) Kurz to improve carotenoid bioavailability. Sci. Rep. 2016, 6, 25426. [CrossRef] [PubMed]
123. Tang, W.H.; Guan, M.C.; Xu, Z.; Sun, J. Pharmacological and pharmacokinetic studies with vitamin D-loaded nanoemulsions in asthma model. Inflammation 2014, 37, 723–728.
124. 2 encapsulated in emulsions: An in vitro and in vivo study. Food Funct. 2017, 8, 767–777. [CrossRef] [PubMed]
125. Parthasarathi, S.; Muthukumar, S.P.; Anandharamakrishnan, C. The influence of droplet size on the stability, in vivo digestion, and oral bioavailability of vitamin E emulsions. Food Funct. 2016, 7, 2294–2302. [CrossRef] [PubMed]
126. Khandavilli, S.; Panchagnula, R. Nanoemulsions as versatile formulations for paclitaxel delivery: Peroral and dermal delivery studies in rats. J. Invest. Dermatol. 2007, 127, 154–162. [CrossRef] [PubMed]
127. Zhou, Y.X.; Zhang, H.; Peng, C. Puerarin: A review of pharmacological effects. Phytother. Res. 2014, 28, 961–975. [CrossRef]
128. Sun, D.; Wei, X.; Xue, X.; Fang, Z.; Ren, M.; Lou, H.; Zhang, X. Enhanced oral absorption and therapeutic effect of acetylpuerarin based on D-α-tocopheryl polyethylene glycol 1000 succinate nanoemulsions. Int. J. Nanomed. 2014, 9, 3413–3423.
129. Higuera-Ciapara, I.; Félix-Valenzuela, L.; Goycoolea, F.M. Astaxanthin: A review of its chemistry and applications. Crit. Rev. Food Sci. Nutr. 2006, 46, 185–196. [CrossRef]
130. Li, M.; Zahi, M.R.; Yuan, Q.; Tian, F.; Liang, H. Preparation and stability of astaxanthin solid lipid nanoparticles based on stearic acid. Eur. J. Lipid Sci. Technol. 2016, 118, 592–602. [CrossRef]
131. Yap, S.P.; Yuen, K.H.; Lim, A.B. Influence of route of administration on the absorption and disposition of α-, γ-and δ-tocotrienols in rats. J. Pharm. Pharmacol. 2003, 55, 53–58. [CrossRef] [PubMed]
132. Abuasal, B.S.; Lucas, C.; Peyton, B.; Alayoubi, A.; Nazzal, S.; Sylvester, P.W.; Kaddoumi, A. Enhancement of intestinal permeability utilizing solid lipid nanoparticles increases γ-tocotrienol oral bioavailability. Lipids 2012, 47, 461–469. [CrossRef] [PubMed]
133. Cho, H.J.; Park, J.W.; Yoon, I.S.; Kim, D.D. Surface-modified solid lipid nanoparticles for oral delivery of docetaxel: Enhanced intestinal absorption and lymphatic uptake. Int. J. Nanomed. 2014, 9, 495–504.
134. Ramalingam, P.; Ko, Y.T. Enhanced oral delivery of curcumin from N-trimethyl chitosan surface-modified solid lipid nanoparticles: Pharmacokinetic and brain distribution evaluations. Pharm. Res. 2015, 32, 389–402. [CrossRef] [PubMed]
135. Rahmani, A.H.; Alsahli, M.A.; Aly, S.M.; Khan, M.A.; Aldebasi, Y.H. Role of curcumin in disease prevention and treatment. Adv. Biomed. Res. 2018, 7, 38. [CrossRef] [PubMed]
136. Adiwidjaja, J.; McLachlan, A.J.; Boddy, A.V. Curcumin as a clinically-promising anti-cancer agent: Pharmacokinetics and drug interactions. Expert Opin. Drug Metab. Toxicol. 2017, 13, 953–972. [CrossRef] [PubMed]
137. Ji, H.; Tang, J.; Li, M.; Ren, J.; Zheng, N.; Wu, L. Curcumin-loaded solid lipid nanoparticles with Brij78 and TPGS improved in vivo oral bioavailability and in situ intestinal absorption of curcumin. Drug Deliv. 2016, 23, 459–470. [CrossRef] [PubMed]
138. Park, S.J.; Garcia, C.V.; Shin, G.H.; Kim, J.T. Development of nanostructured lipid carriers for the encapsulation and controlled release of vitamin D3. Food Chem. 2017, 225, 213–219. [CrossRef]
139. Ohshio, G.; Hosotani, R.; Imamura, M.; Sakahara, H.; Ochi, J.; Kubota, N. Gastrinoma with multiple liver metastases: Effectiveness of dacarbazine (DTIC) therapy. J. Hepatobiliary Pancreat. Surg. 1998, 5, 339–343. [CrossRef]
140. Almousallam, M.; Moia, C.; Zhu, H. Development of nanostructured lipid carrier for dacarbazine delivery. Int. Nano Lett. 2015, 5, 241–248. [CrossRef]
141. Soni, K.; Rizwanullah, M.; Kohli, K. Development and optimization of sulforaphane-loaded nanostructured lipid carriers by the Box-Behnken design for improved oral efficacy against cancer: In vitro, ex vivo and in vivo assessments. Artif. Cells Nanomed. Biotechnol. 2017. [CrossRef] [PubMed]
142. Ullah, M.F. Sulforaphane (SFN): An isothiocyanate in a cancer chemoprevention paradigm. Medicines 2015, 2, 141–156. [CrossRef] [PubMed]